Wockhardt Pharmaceuticals witnessed a significant rally on Friday, with its stock hitting a record high and breaking a 13-year consolidation period. The surge was triggered by the Central Drugs Standard Control Organisation's (CDSCO) approval for the company's newly developed antibiotic, Zaynich, to be marketed in India.
Zaynich: A New Hope Against Infections
Zaynich is an innovative injectable antibiotic, a combination of Zidebactam and Cefepime. Its approval targets the treatment of complicated urinary tract infections (cUTI), including severe kidney infections like pyelonephritis, in adult patients. Crucially, it also addresses cases where these infections are accompanied by Gram-negative bacteremia, a serious bloodstream infection.
This approval positions Wockhardt to tap into a substantial market. The local Indian market for Zaynich is estimated to be between Rs 150-200 crore annually, while the global addressable market is conservatively projected at an impressive $5 billion.
Stock Performance and Market Impact
Following the announcement, Wockhardt shares climbed by 11.50% intraday, reaching a new peak of Rs 1975.50. The company's market capitalization expanded to Rs 31,189 crore. This strong performance marks Wockhardt as the second-best performing stock in the Nifty 500 for May, having risen 36% during the month.
From a technical standpoint, the stock's Relative Strength Index (RSI) stood at 72.3, indicating an oversold condition, often suggesting strong buying interest. The pharma scrip is currently trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages, reinforcing its bullish momentum.
Wockhardt's Commitment to Anti-Infectives
Wockhardt is recognized as a research-based global pharmaceutical and biotechnology company, with a core focus on developing innovative anti-infective solutions. The company's mission is to combat antimicrobial resistance, pioneering next-generation therapies to contribute to a healthier world.